Template For Poster Presentation (Tysa)

3,439 views
2,970 views

Published on

Zonal Topper of the Torrent Young Scholar Award (TYSA) from East
Zone, Year 2009.

0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
3,439
On SlideShare
0
From Embeds
0
Number of Embeds
6
Actions
Shares
0
Downloads
0
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide

Template For Poster Presentation (Tysa)

  1. 1. A STUDY ON MICROALBUMINURIA AS A PREDICTIVE MARKER OF TARGET ORGAN DAMAGE IN HYPERTENSION<br />Tanoy Bose1, R K Kotokey2<br />1 Post Graduate Trainee, 2 Professor & Head, Department of Medicine Assam Medical College & Hospital, Dibrugarh<br />INTRODUCTION<br />CONCLUSIONS<br /><ul><li>Accurate cardiovascular risk evaluation: Cost effective strategy in Rx of Htn.
  2. 2. Microalbuminuria: an integrated marker of target organ damage.
  3. 3. Regression of left ventricular hypertrophy†: Parallels ↓ in MAU regardless of BP changes.
  4. 4. AIMS:
  5. 5. Prevalence of MAU in Htn.
  6. 6. Correlation of MAU with specific TOD d/t Htn</li></ul>.<br /><ul><li>MAU was quite prevalent [37.5%]in patients suffering from Htn
  7. 7. MAU had a + correlation with the </li></ul>1.Duration & Severity of Htn,<br />2.Male sex, 3.Obesity,<br />4.↓ HDL levels (<40mg/dl) 5.↑ LDL levels (>150mg/dl) 6.Retinopathy.7.Evidence of left ventricular hypertrophy.<br />SUMMARY / DISCUSSION<br />METHODS<br /><ul><li>MAU remains to be an important early marker of TOD in hypertension.
  8. 8. An important target for early therapeutic intervention in modulating the course of the disease.</li></ul>RESULTS<br /><ul><li>Non-randomized, cross-sectional, observational study
  9. 9. 128 cases of hypertension : JNC 7 criteria
  10. 10. Duration: 1 year from July 2007 to June 2008
  11. 11. Examined clinically,RoutineInv,CrCl. Lipids ophthalmoscopy, ECG & urine MAU estimation
  12. 12. Incl.Crit: Asymptomatic adults aged > 18yrs with a BP of >140/90 mm Hg
  13. 13. Mean age of patients having MAU : 56.29 ± 9.07 yrs.
  14. 14. Prevalence of MAU ↑ with age [38.88% in 31-40yrs vs 61.53% in >60yrs]
  15. 15. Disease duration of >9yrs: 58.33% vs 18.75% with a duration of 4-6 yrs63.
  16. 16. 63% of male obese had MAU vs 25% of female obese.
  17. 17. Retinopathy : 62.5% of pts with MAU
  18. 18. Retinopathy prevalence ↑with the severity of Htn. [47.6% among Stage II Htnwith MAU vs16.6% among Stage I Htn]
  19. 19. ECG changes of LVH.: 79.16%
  20. 20. MAU : low HDL[<40mg/ml]75%, high LDL [>150mg/dl] 79.16%.
  21. 21. MAU: no correlation with CrCl.</li></ul>REFERENCES<br />†Olsen MH, Wachtell K, Borch-Johnsen K, Okin PM, Kjeldsen SE, Dahlof B, Devereux RB, Ibsen HA:. Losartan Intervention For Endpoint reduction. J Hum Hypertens 16: 591 595, 2002<br />

×